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Abstract
Background: Pharmacogenomic clinical decision support systems (CDSS) have the potential to help overcome
some of the barriers for translating pharmacogenomic knowledge into clinical routine. Before developing a prototype
it is crucial for developers to know which pharmacogenomic CDSS features and user-system interactions have yet
been developed, implemented and tested in previous pharmacogenomic CDSS efforts and if they have been
successfully applied. We address this issue by providing an overview of the designs of user-system interactions of
recently developed pharmacogenomic CDSS.
Methods: We searched PubMed for pharmacogenomic CDSS published between January 1, 2012 and November 15,
2016. Thirty-two out of 118 identified articles were summarized and included in the final analysis. We then compared
the designs of user-system interactions of the 20 pharmacogenomic CDSS we had identified.
Results: Alerts are the most widespread tools for physician-system interactions, but need to be implemented carefully
to prevent alert fatigue and avoid liabilities. Pharmacogenomic test results and override reasons stored in the local EHR
might help communicate pharmacogenomic information to other internal care providers. Integrating patients into
user-system interactions through patient letters and online portals might be crucial for transferring pharmacogenomic
data to external health care providers. Inbox messages inform physicians about new pharmacogenomic test results
and enable them to request pharmacogenomic consultations. Search engines enable physicians to compare medical
treatment options based on a patient’s genotype.
Conclusions: Within the last 5 years, several pharmacogenomic CDSS have been developed. However, most of the
included articles are solely describing prototypes of pharmacogenomic CDSS rather than evaluating them. To support
the development of prototypes further evaluation efforts will be necessary. In the future, pharmacogenomic CDSS will
likely include prediction models to identify patients who are suitable for preemptive genotyping.
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Background
Genetic variants can influence drug metabolism, trans-
port and receptor response and thereby lead to reduced
drug activity or increased toxicity [1–3]. Prominent
examples are the anticoagulants clopidogrel and warfarin
that are metabolized by CYP2C19 and CYP2C9, respect-
ively. Variants in these enzymes can alter the plasma
levels of the anticoagulants and thereby lead to insuffi-
cient anticoagulation or increased risk of bleeding. The
influence of genetic variants on drug activity led to the
development of pharmacogenomic tests and drug dosing
guidelines which incorporate pharmacogenomic data
into the drug prescription process [4, 5]. An example for
the development of pharmacogenomic recommendations
and best practices guidelines is the publicly available web-
based knowledge base PharmGKB (https://www.pharmgk-
b.org/). It includes dosing guidelines by the Clinical
Pharmacogenetics Implementation Consortium (CPIC),
the Royal Dutch Association for the Advancement of Phar-
macy - Pharmacogenetics Working Group (DPWG), the
Canadian Pharmacogenomics Network for Drug Safety
(CPNDS) and other professional society. Other examples
of pharmacogenomic knowledge bases are the OncoKB
(oncokb.org/#/) by the Memorial Sloan Kettering Cancer
Center and the PMKB (https://pmkb.weill.cornell.edu/) by
the Weil Cornell Medical College.
In prospect of whole genome sequencing, the discov-
ery of new gene-drug interaction pairs is very likely and
will further increase the pharmacogenomic knowledge
base. However, translating this pharmacogenomic know-
ledge into clinical routine has been slow and is hindered
by the lack of the physicians’ knowledge and experience
in pharmacogenomic testing [1, 6–8].
In recent years, informatics has gained crucial
relevance for improving patient care. This includes a
considerable amount of published literature which
describes the current efforts on developing and imple-
menting pharmacogenomic clinical decision support sys-
tems (CDSS) [9–11]. Pharmacogenomic CDSS might help
overcome some of the barriers of implementing pharma-
cogenomic knowledge into clinical routine [7, 10].
Pharmacogenomic CDSS are computer-based systems
which support health care providers in prescribing drugs
at the point of care. These systems provide physicians
and other health care providers with reasonably filtered
pharmacogenomic information such as gene-drug inter-
action alerts or patient-specific treatment recommenda-
tions. A pharmacogenomic CDSS can either be integrated
into the local hospital information system (HIS) or used as
a separate program such as a web service or mobile appli-
cation [10]. Furthermore, pharmacogenomic CDSS can
provide passive or active clinical decision support (CDS).
Active CDS include rules and alerts. An alert, for example,
might be triggered because a high-risk drug is prescribed
and pharmacogenomic testing prior to the drug applica-
tion would be indicated. Passive CDS require the user to
actively search for the information, e.g. clicking on a
button or opening a case report [10, 12].
To develop a prototype it is crucial for developers to
know which pharmacogenomic CDSS features and user-
system interactions have been developed, implemented
and tested in previous pharmacogenomic CDSS ef-
forts and if they were successfully applied. Welch and
Kawamoto systematically reviewed the literature on
pharmacogenomic CDSS including manuscripts from
1990 to 2011 [13]. Given the recent rise of omics
technologies, the findings of their systematic review
cannot include the most recent developments of phar-
macogenomic CDSS. In addition to that, Welch and
Kawamoto did not compare the designs of user-system
interactions (e.g. passive vs. active CDS, displaying pre-
testing vs. post-testing alerts, or the contents of such alerts
presented to the user).
Dunnenberger et al. and Hicks et al. previously
reported on recent developments of pharmacogenomic
CDSS since 2012 [14, 15]. They also mentioned some
potential concepts for implementing pharmacogenomic
CDSS into clinical routine. However, they did neither
analyze designs of user-system interactions nor did they
describe whether or not such designs have been evalu-
ated. Furthermore, they limited their scope to concepts
involving an EHR. For developers, it is crucial to also
know which potential designs of user-system interac-
tions exist without involving an EHR.
To our knowledge, there is no systematic or scoping
review to date which provides an overview of the recent
developments of pharmacogenomic CDSS and their
designs of user-system interactions. Given the clinical im-
portance of pharmacogenomic CDSS, we address this
topic by comparing the functionalities and the designs of
user-system interactions of published pharmacogenomic
CDSS since 2012. The objective of this paper is to provide
an overview of the recent developments of pharmacoge-
nomic CDSS and their designs of user-system interactions.
Methods
To minimize bias in the selection of included studies, we
followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) guidelines as far
as appropriate for this scoping review [16, 17]. We
achieved a high degree of completeness by providing
information on 22 out of the 27 points recommended
(see Additional file 1). A study protocol was written
prior to the investigation, but has not been registered.
Information sources and inclusion criteria
We searched PubMed for pharmacogenomic CDSS pub-
lished between January 1, 2012 and November 30, 2016.
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We used the keywords “pharmacogenetic*”, “pharmaco-
genomic*”, “decision support” and “medical decision
making” for the search query as shown in Table 1. The
final search was conducted on December 01, 2016. The
inclusion criteria for the scoping review were as follows:
English article; manuscript in peer-reviewed journal;
research article; describing a clinical prototype or a fully
developed pharmacogenomic CDSS in clinical routine;
describing the functionalities and the design of user-
system interactions of a pharmacogenomic CDSS.
Two authors (MH and MS) screened the titles, index
terms, and abstracts for all identified publications to
determine, if all inclusion requirements were met. This
was done independently by both authors (MH and MS)
and for all identified articles. In this way, potential differ-
ences in the judgment of including or excluding certain
articles could be spotted. If no clear decision could be
made on the basis of this information, the article was
obtained in full-text and a decision on the inclusion was
based on information from the full-text. The full-texts of
all included articles were obtained via institutional
library access or the authors’ user profile on the
ResearchGate platform.
Data abstraction
For all publications meeting the inclusion criteria listed
above, the following data items were extracted by both
authors (MH and MS) independently and for all
included articles: system or project name; users and
study location; CDSS development status; EHR integra-
tion; web-based access; active or passive CDS and the
CDS features for user-system interactions (categorized
as “alerts”, “reports”, “EHR data”, “inbox messages”,
“search engines” and “others”). Differences were discussed
among co-authors (MH, MB, MS) in order to resolve
disagreements and to achieve a consensus. Following this,
all abstracted data were reviewed and revised by all co-
authors, which led to the final version of data abstraction
of all articles.
The system or project name was either the specific
pharmacogenomic CDSS name (if applicable) or (if no
system name existed) the related project name. If neither
a system nor a project name was available, we created a
surrogate pharmacogenomic CDSS name (marked with
s/n for “surrogate name”). Users were defined as physi-
cians, pharmacists, other health care providers or
patients. The study location was the main institution,
where research was conducted. The CDSS development
status was either prototype or fully developed. The EHR
integration category distinguished between pharmacoge-
nomic CDSS which were integrated into an electronic
health record (EHR) or a computerized physician order
entry system (CPOE) (“yes”) and those designed as
stand-alone systems (“no”). A stand-alone system exists
in parallel to the EHR or the CPOE. If the pharmaco-
genomic CDSS was accessible through the internet
(e.g. online portals of laboratories), it was marked as
“web-based access”. The alert category defined whether
the pharmacogenomic CDSS provided pre-testing or post-
testing alerts and which information these alerts
contained. A report was defined as a summary report or
patient letters including the patients’ pharmacogenomic
information. Within the EHR data category every kind of
pharmacogenomic information stored in the EHR for clin-
ical decision support was included. Furthermore, inbox
message designs and search engine designs used for
pharmacogenomic CDSS were documented if applicable.
The risk of bias for individual studies was not system-
atically assessed.
Data analysis and presentation
Extracted and categorized data were used and the data
items were grouped into two logical domains. The first
domain included the categories “system or project
name”, “users and study location” and “CDSS develop-
ment status“. Whereas the second domain comprised
the categories specifying the user-system interaction:
“EHR integration”, “web-based access”, “active or passive
CDS”, “alerts”, “reports”, “EHR data”, “inbox messages”,
“search engines” and “others“. We summarized the
articles in the form of tables and narrative discussion.
Differences were discussed among co-authors (MH, MS)
in order to resolve disagreements and to achieve a con-
sensus. Following this, the results by MH and MS were
reviewed and consented by all co-authors. This led to
the final interpretation and presentation of the
abstracted data of all articles.
To provide an unbiased overview of all pharmacoge-
nomic CDSS including those mentioned in this scoping
review, we grouped all articles which used a common
pharmacogenomic CDSS. The articles were grouped by
the abstracted system or project names and by the attri-
butes of the first domain.
Furthermore, we identified and analyzed the designs of
user-system interactions of recently published pharma-
cogenomic CDSS. Therefore, we used the abstracted
Table 1 PubMed search query
PubMed search query
1. Pharmacogenetics[MeSH Terms]
2. pharmacogenetic*[tw]
3. pharmacogenomic*[tw]
4. “decision support systems, clinical”[MeSH Terms]
5. “decision support”[tw]
6. “decision making”[tw]
7. (“2012/01/01”[PDAT] : “2016/11/30”[PDAT])
8. #1 OR #2 OR #3
9. #4 OR #5 OR #6
10. #7 AND #8 AND #9
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system or project names and the results of the tabulated
attributes of the second domain.
Results
The PubMed search identified 118 potentially relevant
articles. During the title and abstract review, 54 articles
were excluded for not describing a pharmacogenomic
CDSS. The remaining 64 articles underwent full-text
review, after which 12 articles were excluded for not
being primary research articles. Furthermore, 14 articles
were excluded for not describing a clinical prototype or
a fully developed pharmacogenomic CDSS and 12 arti-
cles for not being a primary research article. Six out of
the remaining 38 publications were excluded for not
describing the design of the user-system interaction of
their pharmacogenomic CDSS (Fig. 1).
The 32 publication which had been included were
grouped by the fact of whether or not they used a com-
mon pharmacogenomic CDSS (first domain). Regarding
the articles which reported on the RIGHT project and
the Personalized Medication Program (PMP) we could
not find any information on whether or not they used a
common pharmacogenomic CDSS. We categorized the
pharmacogenomic CDSS by the “Right Drug, Right
Dose, Right Time-Using Genomic Data to Individualize
Treatment (RIGHT)” project (three) and the Personal-
ized Medication Program (PMP) (two) into five separate
and independent systems (Table 2).
As a result we included 31 research articles which have
been published since 2012 and which describe the design
of the user-system interactions of 20 different pharmaco-
genomic CDSS (Table 3). An additional spreadsheet file
shows the features of the 20 pharmacogenomic CDSS in
more detail (see Additional file 2). A further comparison
can be found below (second domain).
EHR integration, web-based access and active or passive
CDS
We identified 14 pharmacogenomic CDSS, which were
integrated into the local EHR and six systems which
were designed as stand-alone systems. Seven pharmaco-
genomic CDSS provided a web-based access to the
pharmacogenomic test results in a password protected
online portal for physicians [10, 18–24] or patients [25–27].
13 pharmacogenomic CDSS provided an active CDSS and
11 CDSS provided a passive CDSS.
Alerts
Designs
In 13 pharmacogenomic CDSS physicians were provided
with actionable real-time alerts for gene-based drug pre-
scription at the point of care. This included pre-test
alerts in six pharmacogenomic CDSS and post-test alerts
in all 13 CDSS. Pre-test alerts were presented when a
physician ordered a drug for a patient for whom there
was no pharmacogenomic test result in the EHR or who
was flagged by a prognostic model for pre-emptive geno-
typing. For instance, in the PREDICT project at the
Vanderbilt University, the prognostic model identified
patients with high risk of initiating simvastatin, warfarin
or clopidogrel therapy within 3 years [20]. When a high-
risk medication is ordered for a patient with a relevant
Fig. 1 PubMed search and process of article selection. CDSS: clinical decision support system
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pharmacogenomic test result in the EHR, a post-test
alert is presented to the physician to guide prescription.
The pre-test alerts of three pharmacogenomic CDSS
presented the clinical impact of a potential drug-gene
interaction to the physician [9, 12, 20, 28–31]. Further-
more, all six pharmacogenomic CDSS with pre-test
alerts included the recommendation that a specific
genotype should be obtained before prescribing the
intended drug if potential drug-gene interactions were
known. One of them [31] recommended consulting a
clinical pharmacist for further treatment evaluation.
Five out of the six pharmacogenomic CDSS offered
an option to order an appropriate pharmacogenomic
test [9, 12, 20, 29–31].
The prescriber could override the pre-test alert in four
pharmacogenomic CDSS [9, 12, 29–31] and continue with
the order or cancellation of the prescription [9, 12, 31]. If
the physician continued with the order, a second
screen prompted the physician in one pharmacoge-
nomic CDSS [9] to enter a pre-defined reason for
overriding the alert.
Links to further information were provided by four phar-
macogenomic CDSS with pre-test alerts [9, 12, 29–31].
Each pre-test alert of these four pharmacogenomic CDSS
Table 2 Selection of 20 pharmacogenomic CDSS
System or project name Users and study location Development status Citation
Clinical Pharmacogenomic
Service (CPS)
Boston Children’s Hospital (BCH);
Physicians Pharmacists
prototype Fusaro et al. 2013 [34];
Manzi et al. 2016 [28]
Medicine Safety Code (MSC) University of Vienna; Physicians and Patients prototype Minarro-Gimenez et al. 2014 [18];
Blagec et al. 2016 [10]
UW-PowerChart® prototype (s/n) University of Washington; Physicians prototype Overby et al. 2012 [37];
Devine et al. 2014 [38];
Overby et al. 2015 [11];
Nishimura et al. 2015 [32];
Nishimura et al. 2016 [33]
CU-case series study (s/n) Columbia University; Physicians fully developed
(CLIA-certified laboratory)
Cabrera und Finkelstein 2012 [26];
Finkelstein et al. 2016 [27]
RIGHT (No.1) Mayo Clinic; Physicians prototype Caraballo et al. 2016 [29]
RIGHT (No. 2) Mayo Clinic; Physicians prototype Vitek et al. 2015 [35]
RIGHT (No. 3) Mayo Clinic; Physicians prototype Ji et al. 2016 [25]
PREDICT Vanderbilt University; Physicians and Pharmacists prototype Pulley et al. 2012 [19];
Peterson et al. 2013 [20]
Personalized Medication Program
(PMP) (No. 1)
Cleveland Clinc (Ohio); physicians prototype Hicks et al. 2016 [30];
Teng et al. 2014 [52]
Personalized Medication Program
(PMP) (No. 2)
Cleveland Clinc (University of Florida) physicians prototype Owusu-Obeng et al. 2014 [36]
PG4KDS St. Jude Children Research Hospital; Physician;
Nurse practitioner; Pharmacists; Patients
prototype Bell et al. 2014 [12];
Hoffman et al. 2014 [39];
Gammal et al. 2016 [31]
GeneSight No study location; Physicians fully developed
(CLIA-certified laboratory)
Altar et al. 2015 [21]
Genomic prescribing system (GPS)
portal
University of Chicago; Physicians; Patients prototype O’Donnell et al. 2014 [22];
Hussain et al. 2016 [23]
CLIPMERGE PGx Mount Sinai Medical Center; Physcians prototype Gottesman et al. 2013 [8]
Pharmacogenetics Testing
Implementation Committee
(PGTIC) (s/n)
National Institutes of Health Clinical Center,
Bethesda, Maryland
prototype Goldspiel et al. 2014 [9]
genAP Oslo University; Physicians prototype Laerum et al. 2013 [40]
YouScript University of Utah; Physicians; Pharmacists fully developed Brixner et al. 2015 [41]
TreatGx University of British Columbia; primary care
physicians; pharmacist
fully developed Dawes et al. 2016 [43]
Coriell Personalized Medicine
Collaborative (CPMC) (s/n)
Ohio State University Wexner Medical Center;
patients
prototype Sweet et al. 2014 [42]
Warfarin Dosing prototype (s/n) Wishard Hospital and Veterans Affairs Medical
Center Indianapolis; Physicians; Pharmacists
prototype Melton et al. 2016 [24]
Notes: “s/n” = surrogate name
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also referred physicians to further resources, so that physi-
cians could learn more about the relevance of pharmaco-
genomic results for drugs with potential drug-gene
interactions.
In addition, the test status was provided in the order set
form in one pharmacogenomic CDSS [9] if the pharmacoge-
nomic result was present, absent, pending, or if the test was
not ordered and the date of the last related test was ordered.
Table 3 Designs of user-system interactions of the 20 selected pharmacogenomic CDSS
System or project name CDSS
integration
Web-based
access
Active or
passive CDS
Included features
Clinical Pharmacogenomic Service (CPS) yes yes active; passive •pre-testing and post-testing alerts
•reports
•EHR data
Medicine Safety Code (MSC) no yes passive •reports
•search engine
•others (interface to upload genetic files;
printed QR codes)
UW-PowerChart® prototype (s/n) yes no active •post-testing alerts
•reports
•EHR data
CU-case series study (s/n) no yes passive •reports
RIGHT (No.1) yes no active •pre-testing and post-testing alerts
•EHR data
•inbox messages
RIGHT (No. 2) yes no active •post-testing alerts
•EHR data
•inbox messages
RIGHT (No. 3) yes yes active •post-testing alerts
•others (online portal for patients)
PREDICT yes yes active; passive •pre-testing and post-testing alerts
•reports
•EHR data
•others (online portal for patients)
Personalized Medication Program (PMP) (No. 1) yes no active; passive •pre-testing and post-testing alerts
•reports
•EHR data
•others (virtual PGx consult)
Personalized Medication Program (PMP) (No. 2) yes no active •post-testing alerts
•inbox messages
PG4KDS yes no active •pre-testing and post-testing alerts
•reports
•EHR data
•inbox messages
GeneSight no yes passive •reports
Genomic prescribing system (GPS) portal no yes active; passive •post-testing alerts
•reports
•search engine
•others (virtual PGx consult)
CLIPMERGE PGx yes no active •post-testing alerts
Pharmacogenetics Testing Implementation
Committee (PGTIC) (s/n)
yes no active •pre-testing and post-testing alerts
•EHR data
•inbox messages
genAP yes no passive •reports
YouScript no no passive •reports
TreatGx yes no passive •EHR data
•inbox messages
Coriell Personalized Medicine Collaborative
(CPMC) (s/n)
no yes passive •reports
•inbox messages
Warfarin Dosing prototype (s/n) yes no active •post-test alerts
Notes: “s/n” = surrogate name
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The post-test alerts of all 13 pharmacogenomic CDSS
presented a problem definition to the physician, which
included the presentation of the raw genotype in the
pharmacogenomic CDSS. Furthermore, the medication
ordered was part of the problem definition in two phar-
macogenomic CDSS [8, 24, 32, 33]. The interpretation
of pharmacogenomic test result (phenotype) was
included in each problem definition. Beside the pheno-
type presentation, all pharmacogenomic CDSS also indi-
cated the clinical impact of a potential drug-gene
interaction in their interpretation of the results. In the
GPS project, a colored traffic signal system informed the
physicians of the different pharmacogenomic risk levels
when prescribing a drug [22, 23]. Red lights signified
drugs with a high risk of severe adverse drug reactions,
yellow lights signified drugs with an increased pharma-
cogenomic risk (caution), and green lights signified
drugs with a favorable pharmacogenomic association.
For all 13 included pharmacogenomic CDSS with
post-test alerts, a recommendation section is described
in the included literature. Within this recommendation,
options for a dosage-adjusted medication based on the
pharmacogenomic results were offered in seven pharma-
cogenomic CDSS [19, 20, 23–25, 28, 34–36]. The recom-
mendation further included contraindication and caution
factors in one out of the seven CDSS [36]. Four additional
pharmacogenomic CDSS advised to select an alternative
medication without dosage-adjustments [8, 9, 32, 33] or
recommended a drug or dose modification [12, 24, 31].
Drugs which should be avoided were displayed in the rec-
ommendation section of three pharmacogenomic CDSS
[25, 30, 35]. For the RIGHT No. 1 project, a recommenda-
tion section was mentioned but not specified or further
described [29].
Override options for the post-test alert were described
in the included articles for ten pharmacogenomic CDSS
[8, 9, 12, 19, 20, 24, 28–33, 36, 37]. The prescribing
physician could choose to continue the order or cancel
the prescription in all of them but one (RIGHT (No.3)
project). Another override option for prescriptions in
the same nine pharmacogenomic CDSS was the modifi-
cation of the initial drug order. If the physician contin-
ued with the order, a second screen prompted the
physician to enter a pre-defined reason for overriding
the alert. According to Manzi et al., physicians of the
GPS project could also enter a free-text reason for over-
riding the alert [28].
Links to further information were described for almost
all (pharmacogenomic CDSS with pre-test alerts except
for the CDSS of the GPS project. Each post-test alert of
the 12 pharmacogenomic CDSS referred physicians to
additional information about related genes or drugs. Six of
them also linked the physicians to full guideline texts and
original references [11, 19, 20, 24, 25, 32, 33, 35, 37, 38].
Another object of the post-test alerts of five pharma-
cogenomic CDSS was a note with contact information of
a clinical pharmacist [28, 30, 32, 33, 36, 39]. The post-
test alert of the GPS project was designed to be read
within 30 s or less [28, 34]. In the PMP No. 2 project,
the raw genotype results were also presented to the
physician when a pharmacogenomic test was ordered
redundantly [36]. The information of the post-test alerts
of the Warfarin Dosing prototype was arranged in four
tabs for structural organization [24].
Evaluation
In the last 5 years, the alert design of the UW-
PowerChart prototype was evaluated three times within
simulated environments. First, Devine et al. evaluated
the alert design with seven cardiologists and three oncol-
ogists. The participants’ median rating of the alerts
usability was two on a Likert scale ranging from one
(strongly agree) to seven (strongly disagree). Some physi-
cians suggested minor improvements to the CPOE user
interface and the alert design [38]. Second, Overby et al.
evaluated the alert design with 15 oncologists and seven
cardiologists. Despite a majority (94%) of physicians
believing in a relative advantage of pharmacogenomic
CDSS, in general only 28% of physicians found the phar-
macogenomic CDSS alerts to be useful. Some physicians
suggested minor improvements to the CPOE user inter-
face and the alert design [11]. Third, Nishimura et al.
evaluated the alert design with 52 physicians. The phar-
macogenomic CDSS interface was appropriate for 87%
of the participants. Most of the participants reported the
alerts to be useful (92%) and at the right time (91%).
Furthermore, 80% of the participants preferred an option
to prescribe the recommended medication within the
alert. Some physicians suggested that supplementary
information should be provided as external links [33].
In a study by O’Donnell et al. the use of the Genomic
Prescribing System (GPS) alerts was evaluated. During
their study period participating patients visited the clinic
268 times. At 86% of the visits, physicians accessed the
pharmacogenomic CDSS and received 367 post-test
alerts for medications of patients. Physicians clicked on
the link within the alert to obtain clinical details
when the alert was indicating a drug with a high risk
(in all cases) or a drug that should be taken with
caution (72% of all cases) [22].
In the RIGHT No.2 project the impact of using alerts
to drive providers toward online pharmacogenomics
education was limited [35].
The pre-test alerts of the pharmacogenomic CDSS of
the PG4KDS project were issued electronically 1106
times and the post-test alerts were issued 1552 times
during the study period. Physicians changed their initial
prescription for 95% of the patients for whom the alerts
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provided treatment recommendations [12]. In a study by
Gammal et al. six patients with high-risk CYP2D6 geno-
types were initially prescribed codeine. Due to a post-test
alert during the order process, the prescriber changed the
order to a recommended alternative analgesic [31].
Six simulated patient scenarios were designed to
evaluate the alert design of the Warfarin Dosing proto-
type. Twelve participating physicians were required to
initiate and adjust warfarin treatments for simulated
patients. Overall, participants believed the alerts were
useful and well designed. However, they also expressed
both some confusion when presented with a warfarin
drug-drug interaction alert for medication not included
in the pharmacogenomic CDSS and some concerns
about ordering an initial dose greater than the standard
starting dose. Therefore, some alert design changes were
suggested by the participating physicians [24].
Reports
Designs
In 12 pharmacogenomic CDSS pharmacogenomic reports
were generated either in the form of summary reports for
physicians [10, 18–22, 26–28, 30–32, 34, 39–41] or in the
form of patient letters for the respective patients [31, 39, 42].
These reports were either generated as HTML pages
[10, 18, 22, 30, 34] or as PDF documents [32, 34]. The
reports are presented to the physician either in the
local EHR - if the pharmacogenomic CDSS was inte-
grated into the EHR - or in an online portal - if they
are not integrated into the EHR. For the pharmacoge-
nomic reports of three pharmacogenomic CDSS a general
information section including information such as patient
data, sample number, current medication or the ordering
physician was described in the articles [21, 28, 41].
Similar to the pre-test and post-test alerts, the reports
included a problem description in all 12 pharmacoge-
nomic CDSS, which contained a genotype results section
and a result interpretation (phenotype) section. Addition-
ally, in the result interpretation section of six pharmacoge-
nomic CDSS the clinical impact of potential drug-gene
interactions was explained [10, 20, 26, 31, 39–42]. The
GeneSight system uses a colored traffic signal system,
which informs physicians of the different pharmacoge-
nomic risk levels when prescribing a drug. Red lights
signify drugs with a high risk of severe adverse drug
reactions, yellow lights signify drugs with an increased
pharmacogenomic risk (caution), and green lights signify
drugs with a favorable pharmacogenomic association [21].
Similarly, in the YouScript system the results were severity-
coded (change, consider, monitor, no change) [41].
For seven of the 12 pharmacogenomic CDSS with phar-
macogenomic result reports, a recommendation section
was mentioned in the articles [10, 18, 26, 28, 31, 39–41]
but only for five of them a further description could be
found in the included literature [10, 18, 26, 31, 39, 41].
Within these five pharmacogenomic CDSS, dosage-
adjusted medication options based on the pharmacoge-
nomic results were recommended. Drugs which should be
avoided were displayed in the recommendation section of
three pharmacogenomic CDSS.
In the patient letter of the CPMC project, patients
were advised to discuss the pharmacogenomic results
with their physicians whenever they were prescribed a
medication which was affected by these results [42].
Further sources of information were provided by five
pharmacogenomic CDSS [10, 28, 31, 39, 40, 42]. Each
report of these CDSS referred physicians or patients
to additional information about related genes or drugs
[28, 31, 39, 40] or to full guideline texts and references
[10, 40, 42]. Another object of the pharmacogenomic
report in the PG4KDS project was a note with contact
information referring to a clinical pharmacist [31, 39].
Evaluation
Blagec et al. evaluated the perception and usability of the
interactive HTML reports of the MSC pharmacogenomic
CDSS amongst 28 physicians and 11 pharmacists [10].
According to Blagec et al. the MSC system was usable
(Cronbach’s alpha 0,8), trustworthy (Cronbach’s alpha 0,7)
and useful (Cronbach’s alpha 0,7). The results of the work-
flow integration subscale were heterogeneous. Most of the
participants were able to solve the presented patient sce-
narios with the recommendations displayed on the phar-
macogenomic CDSS interface. Participants frequently
requested specific listings of alternative drugs and con-
crete dosage instructions. A common problem among the
participants was the negligence of other patient-specific
factors such as co-medications or co-morbidities when
choosing a drug based on the pharmacogenomic CDSS
recommendations [10].
O’Donnell et al. evaluated the pharmacogenomic sum-
mary reports of the Genomic Prescribing System (GPS) by
surveying 60 physicians. Eighty-six percent of the partici-
pants reported that the provided pharmacogenomic sum-
mary reports were clinically relevant (“strongly agree”:
10%, “somewhat agree”: 76%) [22].
Laerum et al. evaluated the pharmacogenomic CDSS
reports of the genAP project in a simulated environment
with nine participating physicians. All physicians rated
the contents of the pharmacogenomics CDSS as useful,
trustworthy, clearly presented and worthwhile logging
into the system. Nevertheless, the explanation of the
report algorithm led to considerable confusion amongst
the participants. On average, physicians needed more
than 40 s to study and understand the report structure.
According to Laerum et al., background information and
references should be included in the reports, but less
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prominently displayed than the results and recommen-
dations [40].
Brixner et al. reported that the physicians’ satisfaction
with the pharmacogenomic CDSS reports of the You-
Script system was high. Ninety-five percent of all physi-
cians considered the pharmacogenomic CDSS to be
helpful for clinical decision-making. However, it might
be important to mention that the software company
Genelex (vendor of YouScript) supported this study by
providing buccal swab collection materials, shipping,
genotyping and support for the pharmacogenomic CDSS
(YouScript) report [41].
EHR data
Designs
Another feature of ten pharmacogenomic CDSS was
the ability to store pharmacogenomic results in the
EHR. In four pharmacogenomic CDSS the generated
pharmacogenomic reports were stored in the EHR and
made available to physicians during clinical routine
[19, 20, 30, 34, 39] (four of them stored summary re-
ports in the lab section [19, 20, 30, 34] and one did so
with patient letters [39]). Another CDSS provided a
hyperlink in the lab section to display the content of
the pharmacogenomic report in PDF format [42].
Raw pharmacogenomic results in form of genotype
results were stored in the lab section of the EHR in eight
pharmacogenomic CDSS [9, 19, 28, 30, 32–35, 39, 43].
One of them stored not only genotype results relevant
to the patients’ current medication, but all available
pharmacogenomic test results, to get an overview of all
pharmacogenomic tests ordered for this patient so far
[20]. Three out of eight pharmacogenomic CDSS
entered the results in a special problem list within the
lab section for a better overview [28–30, 34].
Four out of eight pharmacogenomic CDSS also pro-
vided a phenotype interpretation in the EHR [19, 20, 30,
32, 39], three of them in the lab section [19, 20, 32, 39].
Beside phenotype interpretation, two pharmacogenomic
CDSS further explained the clinical significance of the
pharmacogenomic test results in the EHR [30, 32].
In one pharmacogenomic CDSS dosage-adjusted medi-
cation options which were based on pharmacogenomic
test results were also stored in the EHR [43]. Goldspiel et
al. mentioned in their article that override reasons would
be passed on to the medication order tracking field, to
communicate this information to other care providers
when reordering, verifying, dispensing or administering
this medication [9].
Evaluation
Overby et al. evaluated the pharmacogenomic informa-
tion stored in the EHR in a simulated environment with
15 oncologists and seven cardiologists. Fifty percent of
participating physicians believed, that the genetic test
results within the EHR laboratory section were useful.
Some physicians suggested minor improvements of the
user interface of the UW-PowerChart prototype [44].
According to Peterson et al. the pharmacogenomic
CDSS designs of the PREDICT project were accepted by
the participating clinicians and the Pharmacy and Thera-
peutics committee. However, subsequent changes were
required. For the laboratory section of the EHR, partici-
pants preferred to display any pharmacogenomic test
result, whether indicating a relevant gene variant or not.
This might enable physicians to determine, if a patient
has already been tested or not [20].
Inbox messages
When a new entry was added to the problem list in the
EHR [39] or a new pharmacogenomic test result was
either available in the EHR [9, 29, 35, 36, 43] or in the
web portal [42], an automated inbox message was sent
to a physician or nurse practitioner in nine pharmacoge-
nomic CDSS [9, 29–31, 35, 36, 39, 42, 43]. The inbox
messages contained patient data such as the patient’s
name, medical record number and pharmacogenomic
data, such as gene name and phenotype interpretation.
In one pharmacogenomic CDSS, links to additional
information about related genes, full guideline texts and
original references were provided [35]. Another feature
of two pharmacogenomic CDSS was a pharmacoge-
nomic consultation for physicians. Physicians could
request a consultation through an EHR message to a
pharmacist. The following consultation took place
either virtual in form of a text message response or
in person [22, 30].
Search engines
Search engines were part of two pharmacogenomic
CDSS [18, 22, 23]. They enabled prescribers to consider
pharmacogenomic information when comparing drug
treatments for given clinical indications. In the GPS pro-
ject the search results were tabulated. Furthermore they
were displaying the chosen drug, the related pharmaco-
genomic risk level in form of potential gene-drug inter-
actions and the level of evidence for this drug as an
appropriate treatment for the disease [22, 23]. Addition-
ally, links to additional information were provided. In
the MSC system a physician could use the search engine
in two different ways [18]. First, he or she selected a
medication and a known genetic variant of the patient to
receive recommendations on drug dosing or alternative
treatment. Second, he or she could select a medication
and see all possible recommendations, which were
programmed into the MSC system and which could
potentially be displayed to a physician within a report.
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Others
Designs
The MSC system provided an interface to upload a pa-
tient’s genetic profile from 23andMe or VCF (Variant Call
Format) files to generate a MSC QR (Quick Response)
code. This interface comprised both an instruction to
guide the upload process and to select a file format of
strand orientation, and a file uploader tool. The generated
QR codes were printed on both paper-based lab reports
for physicians and personalized cards for patients to trans-
port and use the genetic information for clinical decision
support [18].
If a drug was ordered in the PGTIC project, the status
of the drug-related pharmacogenomic test was displayed
on the order form (whether the result was present,
absent, pending, or whether the test has not yet been
ordered). Furthermore, order options were provided in
the form of predefined override options or in the form
of a notice that the prescription ordering has been
blocked [9].
Furthermore, in the pharmacogenomic CDSS of the
RIGHT (No. 3) and the PREDICT project, an online
portal for patients was included. Patients could access
their pharmacogenomic test results via this online
portal [19, 20, 25].
Evaluation
According to Peterson et al. 2013, the online patient
portal of the PREDICT project was deemed to be useful.
Patients stated that they preferred detailed and descrip-
tive background information about their genotype-
related risk of side effects [20].
Discussion
Within the last 5 years, several pharmacogenomic CDSS
have been developed which have the potential to support
the incorporation of pharmacogenomic testing into clin-
ical routine. They comprise different forms of active and
passive CDS targeting both physicians and pharmacists.
However, most of the included articles are solely
describing prototypes of pharmacogenomic CDSS rather
than evaluating them.
We performed a literature research to conduct a scop-
ing review of the designs of user-system interactions of
pharmacogenomic CDSS. We limited our PubMed
search to the articles published between January 1, 2012
and November 30, 2016 to focus on pharmacogenomic
CDSS which were recently developed and published.
Nevertheless, we might have neglected relevant designs
of user-system interactions published before 2012.
We found pre-test and post-test alerts to be amongst
the most cited user-system interactions within recently
published pharmacogenomic CDSS. As mentioned by
Bell et al. pharmacogenomic test results remain relevant
to the medical treatment of a patient over his/her life-
time, and need to be stored in a way that they will not
be forgotten or lost [12].
Recommendations, which are presented in a pharma-
cogenomic alert, need to be formulated carefully for sev-
eral reasons. First, other variables besides genetics such
as “comorbidities” or “co-medications” should be consid-
ered when prescribing drugs [10]. Therefore Manzi et al.
refrained from using words such as “should” or “must”
and from dictating exact dosing adjustment recommen-
dations [28]. Second, presenting specific drug alterna-
tives or dose adjustment recommendations in an alert
might also raise concerns about the liability in case of an
adverse drug event, especially when different guidelines
are displayed for the same drug [10, 33].
In this context, alert fatigue has been mentioned as
another main challenge for using alerts within pharma-
cogenomic CDSS [25, 28, 38]. To avoid over-alerting
caused by repetitive alerts Ji et al. [25] included exclu-
sion criteria in the rules and Manzi et al. [28] designed
their alerts to only notify if an action is recommended
by the physician. Both strategies should be considered
and combined when implementing alerts into pharmaco-
genomic CDSS.
Overcoming technical barriers seems to be another
main challenge in designing alerts for a pharmacogenomic
CDSS. For instance, Nishimura et al. intended to link phy-
sicians directly from the alert to the patient’s pharmacoge-
nomic lab results in the local EHR. In their study, such a
link was considered to be useful for user-system interac-
tions. However, due to restrictions of the vendor-based
CDSS it was impossible for Nishimura et al. to integrate
such a link into the post-test alerts [33].
Only four alert designs of pharmacogenomic CDSS
have been evaluated since 2012 and were described in
seven articles. Three studies relating to two pharmacoge-
nomic CDSS demonstrated that alerts can lead to a
change of the initial prescription and therefore prevent
severe adverse drug events effectively [12, 22, 31]. These
order changes can be seen as the physician’s acceptance
of the pharmacogenomic CDSS alert. Furthermore, the
physicians’ acceptance of the UW-PowerChart prototype
alerts has been high [11, 33, 38]. In contrast, using alerts
to drive providers towards online pharmacogenomics
education might be ineffective [35].
The acceptance of pharmacogenomic CDSS reports
was high amongst those physicians and pharmacists who
participated in the four studies that evaluated four differ-
ent pharmacogenomic CDSS [10, 22, 40, 41].
Delivering pharmacogenomic information not only to
physicians but also to patients might be a crucial feature
of pharmacogenomic CDSS. Pharmacogenomic informa-
tion is usually gathered within the environment of a
particular clinic or health care provider. Via patient
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letters [18, 31, 39, 42] and online portals [25], which
contain the pharmacogenomic test results, this informa-
tion can be transferred to other health care providers.
For instance, patients can be advised to discuss their
pharmacogenomic test results with physicians whenever
a medication is prescribed which is affected by these
pharmacogenomic results [42]. In the evaluation study
by Peterson et al. the online patient portal of the PRE-
DICT project was deemed to be useful and was accepted
by participating patients [20].
Another essential function of many pharmacogenomic
CDSS was storing pharmacogenomic information in the
EHR. For instance, if override reasons for alerts are
passed on to the order tracking field of a medication,
they can be communicated to other care providers when
they reorder, verify, dispense or administer this medica-
tion [9]. Furthermore, the storage of all pharmacoge-
nomic test results (not only of the relevant ones) in a
patient’s medical record offers physicians an overview of
all pharmacogenomic tests which have already been
carried out. As a result, reordering the same pharmaco-
genomic test might be avoided [20]. Collecting all phar-
macogenomic information in a separate problem list
within the laboratory section might also serve as an
option for a quick overview of all potential gene-drug
interactions known for a particular patient [28–30, 34].
11 out of 22 physicians who participated in the evalu-
ation study by Overby et al. believed that the genetic
test results within the EHR laboratory section were
useful [44].
Via inbox messages physicians can be informed about
new pharmacogenomic test results, which are available
within the laboratory section of a patients’ medical
record [9, 29, 31, 35, 36, 39, 42, 43]. If the physician
needs any kind of advice regarding the pharmacoge-
nomic test results, he/she might request a consultation
by sending a message to a clinical pharmacist [22, 30].
This provides the physician with an active decision
support before he/she orders a particular medication at
the point-of-care.
With a search engine physicians are enabled to search
for a disease indication and compare various medical
treatment options based on a patient’s pharmacoge-
nomic information. The benefit of such a user-system
interaction is that physicians can get the decision sup-
port before they decide which medication they want to
prescribe. In contrast, the use of alerts requires the
physician to first select a medication before getting the
pharmacogenomic information in response [18, 22, 23].
Recommendations for the implementation of a par-
ticular design of user-system interaction can only be
made on a very high level since the recently developed
pharmacogenomic CDSS have not been sufficiently eval-
uated yet within a clinical setting. Implementing pre-test
or post-test alerts seemed to be the most popular
approaches. However, such active CDS tools require a
comprehensive and well-curated pharmacogenomic
knowledge base. Such a knowledge base has to be both
developed and maintained by physicians with sufficient
knowledge of pharmacogenomic CDSS prior to the
implementation of pharmacogenomic alerts. We recom-
mend the establishment of both the necessary group of
medical experts and the corresponding knowledge base
in order to further evaluate pharmacogenomic alerts.
However, we recommend the implementation of a
passive CDS in the form of structured pharmacogenomic
reports in the first instance. Clinical reports for clini-
cians have been well-established in clinical environments
over many years [45–47] even though such reports
might be unstructured or incomplete in some cases
[48, 49]. Therefore, we believe that the implementa-
tion of a structured pharmacogenomic report would
most likely fit into the working habit of a clinician.
Future pharmacogenomic CDSS will likely include
prediction models to recommend pre-emptive genotyp-
ing for patients exceeding particular risk thresholds. A
patient’s diagnosis might be, contain or induce a risk
factor, which will likely require a medication with known
gene-drug interactions within the next few years. When-
ever such a diagnosis is entered into a patient’s medical
record, an alert might be set off, which recommends
pre-emptive genotyping [50, 51]. This will further
enhance the usefulness of integrating alert and inbox
message options into a pharmacogenomic CDSS. Predic-
tion models have previously been used, but only to iden-
tify potential patients for a pharmacogenomic CDSS
study [20, 25]. Nevertheless, risk thresholds or risk
scores should be defined carefully and in consensus with
the medical staff in charge. Otherwise, inadequate risk
thresholds might lead to over-alerting and alert fatigue.
A limitation of this study is its methodological rigor as
compared to a full systematic review. This is especially
relevant to the selection of the source databases. We
only used the MEDLINE Database, which might limit
the completeness of our search. However, we believe
that our adherence to high methodological standards
throughout this review as defined in the PRISMA state-
ment helps to minimize bias on study selection and
reporting of evidence.
We used the keywords “pharmacogenetic*”, “pharmaco-
genomic*”, “decision support” and “medical decision mak-
ing” for the search query. These are the most common
terms in literature to describe a pharmacogenomic CDSS.
It is possible that these keywords did not cover all phar-
macogenomic CDSS published since 2012. In our opinion,
using the most common terms was sufficient to provide a
broad range of the designs of user-system interactions
which were used in recently published pharmacogenomic
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CDSS. To conduct a systematic review of this topic, an
advanced search query with further relevant terms might
be preferable
We did not assess the risk of bias. The reader there-
fore cannot assess the validity of the individual studies
included in this scoping review.
As this review is intended to describe the functionality
and designs of user-system interactions of pharmacoge-
nomic CDSS, it is also limited in collecting evidence for
the effectivity and the overall medical usability of CDSS
for pharmacogenomics in the clinical setting.
Evaluating the users’ acceptance of designs of user-
system interactions was part of only a few articles in our
scoping review. Further evaluation efforts addressing this
topic will be necessary will be necessary to support the
development of prototypes.
Conclusion
Pre-testing and post-testing alerts seem to be the most rele-
vant designs to physician-system interactions in the 20 phar-
macogenomic CDSS. Such alerts need to be implemented
carefully to prevent alert fatigue and to avoid liabilities. In
addition, pharmacogenomic test results and override rea-
sons which are stored in the local EHR can help to commu-
nicate pharmacogenomic information to other internal care
providers. Integrating patients into user-system interactions
via patient letters and online portals are crucial for transfer-
ring pharmacogenomic data to external health care pro-
viders. Furthermore, inbox messages can inform physicians
about new pharmacogenomic test results and enable them
to request pharmacogenomic consultations. Search engines
enable physicians to compare medical treatment options
based on a patient’s genotype. To support the development
of prototypes further evaluation efforts regarding the designs
of user-system interactions will be necessary. In the future,
pharmacogenomic CDSS will likely include prediction
models to identify patients who are suitable for preemptive
genotyping.
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